Marc Nasoff

USPTO Granted Patents = 15 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 65(Granted Patents)

Company Filing History:

Life Technologies Corporation

patents

2 out of 21

Elanco Tiergesundheit Ag

patents

4. 1 out of 389

Genetics Institute, Inc.

F. Hoffmann-la Roche Ag

patents

8. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2022

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11319377 - Monoclonal antibodies and methods of use (2022-05-03),

2. 9790280 - Monoclonal canine CD20 antibodies and methods of use (2017-10-17),

3. 8637264 - Microarrays and uses therefor (2014-01-28),

4. 8173128 - Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody (2012-05-08),

5. 8101182 - Methods and compositions for treating allergic diseases (2012-01-24),

6. 8097705 - Methods and compositions for treating allergic diseases (2012-01-17),

7. 8012703 - Microarrays and uses therefor (2011-09-06),

8. 7888483 - Antagonists of protease activated receptor-1 (PAR1) (2011-02-15),

9. 7863008 - Method for detecting NANBV associated seroconversion (2011-01-04),

10. 7794946 - Microarray and uses therefor (2010-09-14),

11. 7229617 - Methods and compositions for inducing apoptosis in cancer cells (2007-06-12),

12. 6723555 - Multi-sample fermentor and method of using same (2004-04-20),

13. 6692751 - Methods and systems for producing recombinant viral antigens (2004-02-17),

14. 6635441 - Multi-sample fermentor and method of using same (2003-10-21),

15. 5030563 - Bacterial hypersecretion using mutant repressor sequence (1991-07-09),

Title: The Innovative Journey of Marc Nasoff: Pioneering Cancer Treatment through Monoclonal Antibodies

Introduction: Marc Nasoff, an innovative inventor based in San Diego, California, has made significant contributions to the field of biomedicine. With a total of 15 patents to his name, Nasoff's work primarily focuses on leveraging monoclonal antibodies for cancer treatment, showcasing his dedication to improving the lives of both humans and animals.

Latest Patents: Nasoff's latest patents emphasize his commitment to advancing medical technology. His patent on "Monoclonal antibodies and methods of use" details the development of immunogens and monoclonal antibodies that assist in the identification and treatment of cancer cells, including those found in dogs. Notably, his work on "Monoclonal canine CD20 antibodies and methods of use" highlights the use of chimeric anti-canine CD20 antibodies therapeutically to treat lymphoma in dogs, further proving his innovative approach to veterinary oncology.

Career Highlights: Throughout his professional journey, Marc Nasoff has collaborated with prominent companies such as Irm LLC and Life Technologies Corporation. His experience in these organizations has not only shaped his expertise but also allowed him to develop groundbreaking inventions that have the potential to change cancer treatment paradigms.

Collaborations: In his pursuit of innovation, Nasoff has teamed up with talented individuals like Quinn L Deveraux and James P Hoeffler. These collaborations have fostered a creative environment that has driven their shared passion for scientific advancement, allowing them to address complex challenges related to cancer treatment.

Conclusion: Marc Nasoff's innovative spirit has led him to develop valuable patents in the field of monoclonal antibodies. His commitment to both veterinary and human medicine marks him as a notable figure in the landscape of medical invention. As he continues to explore new frontiers in biomedicine, the impact of his work will undoubtedly resonate for years to come.

This text is generated by artificial intelligence and may not be accurate.